Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study

BACKGROUND: Speculations whether treatment with angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin II receptor blockers (ARB) predisposes to severe coronavirus disease 2019 (COVID-19) or worsens its outcomes. This study assessed the association of ACE-I/ARB therapy with the development...

Descripción completa

Detalles Bibliográficos
Autores principales: Hakeam, Hakeam A., Alsemari, Muhannad, Duhailib, Zainab Al, Ghonem, Leen, Alharbi, Saad A., Almutairy, Eid, Sheraim, Nader M. Bin, Alsalhi, Meshal, Alhijji, Ali, AlQahtani, Sara, Khalid, Mohammed, Barry, Mazin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010897/
https://www.ncbi.nlm.nih.gov/pubmed/33231487
http://dx.doi.org/10.1177/1074248420976279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010897/
https://www.ncbi.nlm.nih.gov/pubmed/33231487
http://dx.doi.org/10.1177/1074248420976279

Ejemplares similares